quinazolines has been researched along with Colonic Neoplasms in 188 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (7.98) | 18.7374 |
| 1990's | 31 (16.49) | 18.2507 |
| 2000's | 79 (42.02) | 29.6817 |
| 2010's | 56 (29.79) | 24.3611 |
| 2020's | 7 (3.72) | 2.80 |
| Authors | Studies |
|---|---|
| Artru, P; Auclin, E; Basile, D; Coutzac, C; Dior, M; Dubreuil, O; Faroux, R; Gallois, C; Hafliger, E; Hautefeuille, V; Locher, C; Palmieri, LJ; Pellat, A; Pernot, S; Perret, A; Randrian, V; Taieb, J; Turpin, A | 1 |
| Liang, J; Liu, J; Liu, S; Lu, L; Pan, F; Shen, R; Wang, J; Xin, FZ; Yang, C; Zhang, N | 1 |
| Cao, Y; Chen, M; Li, J; Lu, M; Peng, Z; Qi, C; Shen, L; Wang, X; Wang, Z; Zhang, J; Zhang, Q | 1 |
| Christou, YA; Dietis, N; Georgiades, SN; Ilmi, R; Odysseos, AD; Pitris, C; Stylianou, P; Tseriotou, E; Ttofi, I | 1 |
| Chen, J; Lin, H; Peng, Y; Wang, J | 1 |
| Chen, S; Cheng, J; Dong, G; Fang, K; Huang, Y; Li, Y; Sheng, C; Wang, L; Wu, S | 1 |
| Cui, MZ; Deng, Y; He, BC; Hu, Y; Huang, J; Li, FS; Li, L; Li, PP; Shu, DZ; Zeng, JR | 1 |
| Chambers, C; Giani, J; Sawyer, MB | 1 |
| Ding, K; Ding, Y; Wang, J; Xu, D; Yuan, Y; Zhu, N | 1 |
| Andersson, C; Blom, K; Edqvist, PH; Fryknäs, M; Gustafsson, MG; Jarvius, M; Larsson, R; Nazir, M; Nyberg, F; Nygren, P; Senkowski, W | 1 |
| Choo, J; Chung, HY; Heo, G; Im, E; Jung, JH; Jung, Y; Kim, DH; Kim, MJ; Kim, SJ; Kim, W; Lee, Y; Moon, HR; Noh, TH; Son, S | 1 |
| Chae, YC; Kim, JY; Kim, KB; Lee, KH; Oh, H; Park, JW; Seo, SB | 1 |
| He, K; Yu, J; Zhang, L; Zheng, X | 1 |
| Ponnurangam, S; Rangarajan, P; Standing, D; Subramaniam, D | 1 |
| Brewer, M; Janakiram, NB; Mohammed, A; Rao, CV; Steele, VE; Vedala, K | 1 |
| Lewis, TC; Prywes, R | 1 |
| El-Mashtoly, SF; Gerwert, K; Kötting, C; Mosig, A; Petersen, D; Reinacher-Schick, A; Yosef, HK | 1 |
| Chan, TA; Luwor, RB; Mariadason, JM; Ng, I; Putoczki, TL; Stylli, SS; Ung, N; Zhu, HJ | 1 |
| Buck, JR; Cheung, YY; Coffey, RJ; Dawson, ES; Hight, MR; Manning, HC; Nickels, ML; Saleh, S; Tang, D; Washington, MK; Zhao, P | 1 |
| Chen, PJ; Huang, GB; Li, B; Lou, YF; Luo, XY; Yu, XR; Zheng, DQ; Zou, ZZ | 1 |
| Fang, Y; Febles, NK; Ferrie, AM | 1 |
| Fadlalla, K; Gales, DN; Manne, U; Putcha, BD; Samuel, T | 1 |
| Asbagh, LA; Baietti, MF; Budinska, E; De Vriendt, V; Hoe, N; Imjeti, NS; Jacobs, B; Sablina, A; Singh, S; Steklov, M; Tejpar, S; Vazquez, I; Vecchione, L; Zimmermann, P | 1 |
| Hua, X; Jin, J; Katona, BW; Liu, Y; Ma, A | 1 |
| Aga, MA; Ali, S; Behl, A; Hamid, A; Hussain, A; Khan, S; Mondhe, DM; Qazi, AK; Saxena, AK; Shah, BA; Singh, SK; Taneja, SC | 1 |
| Abreu, LM; Costa-Lotufo, LV; Jimenez, PC; Mafezoli, J; Mattos, MC; Oliveira, MC; Pfenning, LH; Pinto, FC; Rodrigues, BS; Rodrigues-Filho, E; Sahm, BD | 1 |
| Ashinuma, H; Sekine, I | 1 |
| Adolf, GR; Apgar, J; Garin-Chesa, P; Haaksma, E; Hofmann, MH; Kessler, D; Kraut, N; Quant, J; Sanderson, MP; Savchenko, A; Schaaf, O; Treu, M; Tye, H; Zahn, SK; Zoephel, A | 1 |
| Chen, QZ; Chen, ZH; He, BC; Huang, J; Li, Y; Ren, CM; Shao, Y; Sun, WJ; Wang, DX; Wu, K; Wu, QX; Yu, Y; Yuan, SX; Zeng, YH | 1 |
| Abdel-Aziz, HA; Abdulla, M; Ahmad, R; Al-Kahtani, AA; Al-Obaid, O; Al-Tamimi, AM; Alafeefy, AM; Carta, F; Eldehna, WM; Supuran, CT | 1 |
| Watanabe, A | 1 |
| Fan, Z; Lu, Y; Qiu, S; Shi, C | 1 |
| Chen, L; Cheng, H; Guo, X; Meng, Y; Sheng, X; Tai, G; Zhang, F; Zhou, Y | 1 |
| Ding, Z; Does, MD; Gore, JC; Li, K; Manning, HC; Smith, RA; Waterton, JC; Xu, J; Zhao, P | 1 |
| Abbasi Asbagh, L; Barber, PR; Bosch-Vilaró, A; Jacobs, B; Kim, P; Kirkland, R; Liu, X; Michel, J; Ng, T; Pomella, V; Singh, S; Tejpar, S; Vojnovic, B; Weitsman, G | 1 |
| Cui, Y; He, Y; Liu, M; Ma, H; Qiu, P; Tang, Y; Wang, S; Xu, H; Xu, L; Zeng, X; Zhang, L; Zhang, M | 1 |
| Gong, XL; Huang, C; Liu, H; Wen, B; Wu, LY | 1 |
| Castellani, G; Ceccarelli, C; Coppola, D; Francesconi, M; Guidotti, L; Lauriola, M; Martini, D; Mattei, G; Montroni, I; Pezzetti, F; Rosati, G; Ruggeri, A; Santini, D; Solmi, R; Strippoli, P; Taffurelli, M; Ugolini, G; Voltattorni, M; Zanotti, S | 1 |
| Bedenne, L; Carrato, A; Collette, L; El-Serafi, M; Kerr, D; Labianca, R; Mini, E; Paillot, B; Popov, I; Praet, M; Raffaele Bianco, A; Sanches, E; Sobrero, A; Vincent, M; Welch, J; Wils, J | 1 |
| Antonacopoulou, A; Floratou, K; Giannopoulou, E; Kalofonos, HP; Papavassiliou, AG | 1 |
| Waldman, AS; Wyatt, MD; Yang, Z | 1 |
| Brattain, MG; Hauser, J; Hu, YP; Humphrey, LE; Li, W; Panasiewicz, M; Patil, SB | 1 |
| Boku, N; Fujiwara, Y; Murakami, H; Nokihara, H; Puchalski, TA; Shin, E; Takahashi, T; Tamura, T; Yamada, K; Yamada, Y; Yamamoto, N; Yamazaki, K | 1 |
| Demetter, P; Geurs, F; Knape, S; Ponette, J; Ponette, S; Vandewaeter, S | 1 |
| Norris, CM; Ryan, A; Shi, W; Siemann, DW | 1 |
| Fazzone, W; LaBonte, MJ; Ladner, RD; Lenz, HJ; Louie, SG; Manegold, PC; Wilson, PM | 1 |
| Bastians, H; Kaestner, P; Stolz, A | 1 |
| Amaravadi, R | 1 |
| Beganovic, S | 1 |
| Funato, T; Takeda, M | 1 |
| Botchkina, G; Formentini, A; Ju, J; Kornmann, M; Song, B; Titmus, MA; Wang, Y | 1 |
| Chang, JG; Feng, YH; Lee, JC; Lu, PJ; Shiau, AL; Shieh, GS; Tsao, CJ; Wu, CL; Yeh, KT | 1 |
| Fan, X; Liang, HP; Wang, X; Xu, X; Yang, X; Zhang, C | 1 |
| Alferez, DG; Goodlad, RA; Ryan, AJ; Wilkinson, RW; Wright, NA | 1 |
| Chen, X; Hoffman, L; Lee, TY; Ryan, AJ; Tai, JH; Tessier, J | 1 |
| Banerjee, D; Bertino, JR; Blasberg, RG; Cai, S; de Stanchina, E; Kochetkov, T; Moroz, MA; Nair, J; Schwartz, GK; Serganova, I; Shamis, M; Wu, J | 1 |
| Azzariti, A; Bocci, G; Chiarappa, P; Del Bufalo, D; Del Tacca, M; Fioravanti, A; Mangia, A; Paradiso, A; Porcelli, L; Quatrale, AE; Sebastian, S; Simone, GM; Sini, P | 1 |
| Almendro, V; Ametller, E; Casas, I; Fernández-Nogueira, P; García-Recio, S; Gascón, P; Mayordomo, C; Pastor-Arroyo, EM; Vinyals, L | 1 |
| Dicker, DT; Dolloff, NG; El-Deiry, WS; Hart, LS; Humphreys, R; Mayes, PA | 1 |
| Allali-Hassani, A; Arrowsmith, CH; Barsyte-Lovejoy, D; Brown, PJ; Chen, X; Frye, SV; He, Y; Herold, JM; Huang, J; Jin, J; Liu, F; Vedadi, M; Yates, CM | 1 |
| Chen, H; Cui, B; Jin, Y; Wang, X; Yu, Z | 1 |
| Budak, K; Pestalozzi, B; Weisshaupt, Ch | 1 |
| Glimelius, B; Häggblad Sahlberg, S; Lennartsson, J; Nygren, P; Spiegelberg, D; Stenerlöw, B | 1 |
| Soyibo, AK; Whittle, DO | 1 |
| He, F; Huang, L; Wang, F; Yang, L | 1 |
| Bae, JH; Chung, JS; Kang, CD; Kim, MJ; Kim, SH; Kim, SJ; Oh, SO | 1 |
| Appleyard, CB; Coppola, D; Cruz, ML; Isidro, AA; Pagán, B; Ren, Y; Wu, J | 1 |
| Chouhan, BS; Garofalo, A; Giridhar, R; Grande, F; Naik, PP; Neamati, N; Yadav, MR | 1 |
| Bankaitis, ED; Rinella, ES; Threadgill, DW | 1 |
| Jin, YB; Ko, YG; Lee, JS; Lee, M; Lee, YJ; Lee, YS; Park, JJ; Yi, JY | 1 |
| Cho, NJ; Park, YS | 1 |
| Dai, X; Du, Y; Feng, Y; Li, X; Liu, J; Wang, H; Xia, L; Zhang, J | 1 |
| Bai, YX; Bian, WX; Han, Y; Liu, L; Yuan, HH | 1 |
| Cheng, T; Ge, Z; Li, R; Qiao, K; Zhang, L; Zhang, X | 1 |
| Gao, X; Li, YL; Liu, XX; Ma, XL; Nie, W; Sang, YX; Shen, GB; Shi, HS; Wang, FT; Wei, YQ; Xu, GC | 1 |
| Matsunaga, T; Ogasawara, M; Saiki, I; Suzuki, H; Takahashi, S | 1 |
| Bianco, AR; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Tortora, G; Troiani, T; Veneziani, BM; Zangemeister-Wittke, U | 1 |
| Binetti, P; La Cesa, A; Massacesi, C; Picardi, A; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Attoub, S; Bruyneel, E; Emami, S; Gespach, C; Mareel, M; May, FE; Nguyen, QD; Rodrigue, CM; Rodrigues, S; Thim, L; Westley, BR | 1 |
| Azzariti, A; Colucci, G; Paradiso, A; Xu, JM | 1 |
| Cheng, K; Raufman, JP; Zimniak, P | 1 |
| Geller, J; Houghton, JA; Nagy, K; Petak, I; Szucs, KS; Tillman, DM | 1 |
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; De Vita, F; Melisi, D; Tortora, G; Troiani, T | 1 |
| Darmoul, D; Devaud, H; Gratio, V; Laburthe, M | 1 |
| Ogasawara, M; Suzuki, H | 1 |
| Azzariti, A; Paradiso, A; Porcelli, L; Xu, JM | 1 |
| André, T; de Gramont, A; Gamelin, E; Garcia, ML; Kalla, S; Lenaers, G; Louvet, C; Méry-Mignard, D; Saavedra, A | 1 |
| Isoe, T; Kamishohara, M; Kubo, K; Miura, T; Nakamura, K; Shibuya, M; Taguchi, E; Takahashi, K; Yamamoto, A | 1 |
| Cao, S; Durrani, FA; Rustum, YM | 1 |
| Bocci, G; Danesi, R; Di Paolo, A | 1 |
| Dimitroulakos, J; Goss, G; Hanson, JE; Lagarde, AE; Lorimer, IA; Mantha, AJ | 1 |
| Goldstein, D; Qu, XJ; Russell, PJ; Yang, JL | 2 |
| Brattain, MG; Zhou, Y | 1 |
| Fukushima, M; Hoogeland, MF; Peters, GJ; Temmink, OH | 1 |
| Lindner, H; Loeffler-Ragg, J; Mueller, D; Sarg, B; Skvortsov, S; Skvortsova, I; Witsch-Baumgartner, M; Zwierzina, H | 1 |
| Endo, K; Fujii, Y; Fukai, I; Haneda, H; Iuchi, K; Kawahara, M; Kobayashi, Y; Konishi, A; Kuwabara, Y; Matsumura, A; Mizuno, K; Okumura, M; Sasaki, H; Sugiura, H; Suzuki, E; Takada, M; Tanaka, H; Yano, M | 1 |
| Braun, AH; Dirsch, O; Hilger, RA; Seeber, S; Stark, K; Vanhoefer, U | 1 |
| Kitayama, J; Mori, K; Nagawa, H; Shida, D; Watanabe, T; Yamashita, H | 1 |
| Ballard, P; Bradbury, RH; Harris, CS; Hennequin, LF; Hickinson, M; Johnson, PD; Kettle, JG; Klinowska, T; Leach, AG; Morgentin, R; Ogilvie, DJ; Olivier, A; Pass, M; Warin, N; Williams, EJ | 1 |
| Brattain, MG; Conway, AN; Hauser, J; Hu, YP; Humphrey, L; Li, S; Vinci, MA; Wang, J; Willson, JK; Zborowska, E; Zhou, Y | 1 |
| Buttitta, F; Felicioni, L; Marchetti, A | 1 |
| Chattopadhyay, S; Goldman, ID; Krupenko, N; Krupenko, SA; Zhao, R | 1 |
| Aboagye, E; Pillai, RG; Price, P; Yau, K | 1 |
| Bartralot, R; Bodet, D; García-Patos, V; Heras, C; Mollet, J | 1 |
| Borner, MM | 1 |
| Barrow, D; Gee, JM; Holloway, B; Jones, HE; Nicholson, RI; Tonge, D | 1 |
| Ciardiello, F; Eckhardt, SG; Lockerbie, O; Morrow, M; Troiani, T | 1 |
| Attoub, S; Bruyneel, E; Emami, S; Gespach, C; Grijelmo, C; Nguyen, QD; Rivat, C; Rodrigue, CM; Rodrigues, S | 1 |
| Azzariti, A; Paradiso, A; Porcelli, L; Simone, GM; Xu, JM | 1 |
| Kahlenberg, MS; Krishnegowda, N; Learn, PA; Talamantez, J | 1 |
| Brown, E; Buck, E; Eyzaguirre, A; Gibson, NW; Griffin, G; Haley, JD; Iwata, KK; McCormack, S; Petti, F | 1 |
| Bissonnette, M; Cerda, S; Cohen, G; Dougherty, U; Fichera, A; Gong, C; Hart, J; Jagadeeswaran, S; Joseph, L; Khare, S; Little, N; Mustafi, R; Sehdev, A; Tallerico, M; Tretiakova, M; Turner, JR; Yuan, W | 1 |
| Azzariti, A; Han, Y; Li, YM; Li, ZQ; Paradiso, A; Wang, Y; Xu, JM; Yang, WW; Yuan, SJ; Zhao, CH | 1 |
| Bradley, DP; Checkley, D; Kendrew, J; Kuribayashi, H; Tessier, JL; Waterton, JC; Wedge, SR | 1 |
| Czaykowski, PM | 1 |
| Ciardiello, F; Eckhardt, SG; Gustafson, DL; Henthorn, TK; Lockerbie, O; Long, M; Merz, A; Morrow, M; Serkova, NJ; Troiani, T | 1 |
| Brady, MC; Foote, KM; Green, S; Heaton, SP; Heron, NM; Hill, GB; Jung, FH; Kearney, S; Keen, NJ; Mortlock, AA; Odedra, R; Pasquet, G; Wedge, SR; Wilkinson, RW | 1 |
| Arango, D; Augenlicht, LH; Byun, DS; Goel, S; Jhawer, M; Klampfer, L; Ling, YH; Mariadason, JM; Montagna, C; Nasser, S; Perez-Soler, R; Shin, J; Soler, RP; Wilson, AJ | 1 |
| Aluri, L; Bissonnette, M; Cerda, S; Chumsangsri, A; Cohen, EE; Delgado, J; Dougherty, U; Fichera, A; Hart, J; Jagadeeswaran, S; Joseph, L; Little, N; Mustafi, R; Sehdev, A; Tretiakova, M; Yuan, W | 1 |
| Hirakawa, K; Inoue, H; Mimori, K; Mori, M; Nagahara, H; Ohira, M; Sawada, T; Zhang, X | 1 |
| Benjamin, MB; Hynes, JB; McCue, GH; Yang, YC | 1 |
| Bertino, JR; Cardenas, RM; Fernandes, DJ; Hynes, JB | 1 |
| Bertino, JR; Fernandes, DJ; Hynes, JB | 1 |
| Allegra, CJ | 1 |
| Braña, MF; Castellano, JM; Keilhauer, G; Machuca, A; Martín, Y; Redondo, C; Schlick, E; Walker, N | 1 |
| Banks, SD; Barrett, LL; Dickerson, S; Pendergast, W; Smith, GK; Waters, KA | 1 |
| Dev, IK; Dickerson, SH; Duch, DS; Ferone, R; Pendergast, W; Smith, GK | 1 |
| Lehman, NL; Moran, RG; Smith, SG | 1 |
| Dev, IK; Dickerson, SH; Duch, DS; Ferone, R; Hall, WR; Humphreys, J; Johnson, JV; Kelly, JM; Pendergast, W; Wilson, DC | 1 |
| Banks, S; Dev, IK; Dickerson, SH; Duch, DS; Ferone, R; Heath, LS; Humphreys, J; Knick, V; Pendergast, W; Singer, S | 1 |
| Malmberg, M; Rustum, YM; Slocum, HK; Yin, MB; Zhang, ZG | 1 |
| Kéri, G; Kökösi, J; Kövesdi, I; Mák, M; Orfi, L; Szász, G; Teplán, I | 1 |
| Allegra, CJ; Drake, JC; Johnston, PG; Moran, RG | 1 |
| Arredondo, MA; Matsui, SI; Rustum, YM; Wrzosek, C | 1 |
| Buquet-Fagot, C; Djelloul, S; Gespach, C; Mester, J; Raymond, E | 1 |
| Horowitz, RW; Ladner, RD; Schwartz, EL; Wadler, S; Zhang, H | 1 |
| Bertino, JR; Chang, YM; Chou, TC; Gorlick, R; Izzo, J; Longo, GS; Tong, WP; Zielinski, Z | 1 |
| Adjei, PN; Glenn, KS; Gores, GJ; Karnes, WE; Kaufmann, SH; Kottke, TJ; Weller, SG | 1 |
| Aschele, C; Baldo, C; Bertino, JR; Bornmann, WG; Debernardis, D; Sobrero, AF | 1 |
| McCann, J | 1 |
| Bours, V; Fillet, G; Jerusalem, G | 1 |
| Albanell, J; Baselga, J; Bos, M; Fry, DW; Kim, YM; Mendelsohn, J | 1 |
| Aiba, K; Akazawa, S; Fukuoka, M; Furue, H; Furuse, K; Horikoshi, N; Kanamaru, R; Konishi, T; Kotake, T; Kudoh, S; Kurihara, M; Niitani, H; Ota, K; Sakata, Y; Taguchi, T; Tsukagoshi, S; Wakui, A; Yoshida, S | 1 |
| Endo, W; Haridas, K; Hausheer, FH; Matsui, S; Rustum, YM; Seetharamulu, P; Wrzosek, C | 1 |
| Blaese, RM; Candotti, F; Wildner, O | 1 |
| Jansen, G; Peters, GJ; Pinedo, HM; Smid, K; Smitskamp-Wilms, E | 1 |
| Cunningham, D; Ford, HE | 1 |
| Ford, HE; Jackman, AL; Kimbell, R | 1 |
| Ebata, T; Kikkawa, N; Mitachi, Y; Nishiguchi, Y; Nishisho, I; Osanai, H; Sawai, K; Tsutsui, M; Ujiie, S; Wakasugi, H; Wakui, A; Yasutake, K | 1 |
| Backus, HH; Kuiper, CM; Peters, GJ; Pinedo, HM; van der Wilt, CL; van Triest, B | 1 |
| Kuiper, CM; Peters, GJ; van der Wilt, CL | 1 |
| Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lucia, L; De Vita, F; Orditura, M; Palmeri, S; Rivellini, F | 1 |
| Ahnen, D; Fetter, J; Li, H; Liu, L; Pamukcu, R; Piazza, GA; Sperl, G; Thompson, WJ; Zhu, B | 1 |
| Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW | 1 |
| Jackson, LE; Leach, MO; Maisey, NR; Ronen, SM; Smith, TA; Titley, JC | 1 |
| De Mey, J; Meysman, M; Neyns, B; Schallier, D | 1 |
| Agrawal, S; Chu, E; Schmitz, JC; Yu, D | 1 |
| Akutsu, M; Furukawa, Y; Kano, Y; Suzuki, K; Tsunoda, S; Yazawa, Y | 2 |
| Backus, HH; Bunni, MA; Comijn, L; Jackman, AL; Jansen, G; Mitchell, F; Peters, GJ; Priest, DG; Smid, K; van der Wilt, CL; Veerman, G; Voorn, DA; Wouters, D | 1 |
| Baguley, BC; Bu, X; Deady, LW; Denny, WA; Finlay, GJ | 1 |
| Backus, HH; Jansen, G; Kuiper, CM; Peters, GJ; Pinedo, HM; van Groeningen, CJ; Wouters, D | 1 |
| Matsubara, T; Ogasawara, M; Suzuki, H | 1 |
| Bianco, AR; Caputo, R; Ciardiello, F; Damiano, V; Fontanini, G; Melisi, D; Tortora, G; Veneziani, BM; Zunino, F | 1 |
| Backus, HH; Kuiper, CM; Peters, GJ; Pinedo, HM; van der Wilt, CL; van Groeningen, CJ; Wouters, D | 1 |
| Reutova, EV | 1 |
| Baatar, D; Pai, R; Pavelka, M; Soreghan, B; Szabo, IL; Tarnawski, AS | 1 |
| Boyer, CR; Karjian, PL; Neuteboom, ST; Pegram, M; Wahl, GM | 1 |
| Dubreuil, A; Fischel, JL; Formento, P; Laurent-Puig, P; Magné, N; Milano, G; Poupon, MF | 1 |
| Aherne, GW; Brunton, L; Jackman, AL; Kimbell, R; Melin, CJ; Theti, DS; Walton, M | 1 |
| Aschele, C; Bertino, JR; Nicolin, A; Rosso, R; Sobrero, A | 1 |
| Adkins, DA; Houghton, JA; Houghton, PJ; Rahman, A | 1 |
| Bagshawe, KD; Bradshaw, T; Mellor, B; Melton, RG; Pedley, RB; Searle, F; Sherwood, RF | 1 |
| Brown, TD; Costanza, ME; Grem, JL; King, SA | 1 |
| Bertino, JR; McGuire, JJ; Sobrero, AF | 1 |
| Bertino, JR; Nicolin, A; Romanini, A; Rosso, R; Russello, O; Sobrero, A | 1 |
| Bissery, MC; Corbett, TH; Luk, GD; Mucci-LoRusso, P; Plowman, J; Polin, L; Valeriote, F | 1 |
| Bertino, JR; Sobrero, AF | 1 |
| Bertino, JR; McGuire, JJ; Rodenhuis, S; Sawicki, WL | 1 |
| Bertino, JR; Handschumacher, RE; Sobrero, AF | 1 |
| Cantwell, BM; Harris, AL | 1 |
| Atassi, G; Dykes, DJ; Harrison, SD; Kabbe, HJ; Narayanan, VL; Paull, KD; Plowman, J; Yoder, OC | 1 |
| Atassi, G; Dumont, P; Kabbe, HJ; Yoder, O | 1 |
| Cantwell, BM; Harding, MJ; Harris, AL; Kaye, SB; Milstead, RA | 1 |
| Hynes, JB; Kumar, A; Tomazic, A; Washtien, WL | 1 |
| Bertino, JR; Hynes, JB; McGuire, JJ; Sobrero, AF | 1 |
8 review(s) available for quinazolines and Colonic Neoplasms
| Article | Year |
|---|---|
Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Humans; Network Meta-Analysis; Phenylurea Compounds; Pyridines; Pyrrolidines; Quinazolines; Rectal Neoplasms; Thymine; Trifluridine; Uracil | 2019 |
Fruquintinib effectively controlled the advanced small bowel adenocarcinoma progressed after multiple lines of palliative treatment: a case report and literature review.
Topics: Adenocarcinoma; Benzofurans; Colonic Neoplasms; Humans; Intestine, Small; Male; Middle Aged; Palliative Care; Quinazolines | 2020 |
[Companion Diagnostics for Solid Tumors].
Topics: Anaplastic Lymphoma Kinase; Biomarkers, Tumor; Breast Neoplasms; Cetuximab; Colonic Neoplasms; Crizotinib; Diagnostic Uses of Chemicals; Drug Discovery; ErbB Receptors; Gefitinib; Gene Fusion; Guidelines as Topic; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Pharmacogenetics; Precision Medicine; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Trastuzumab | 2015 |
[Current update and testing procedures for genetic diagnosis in malignant neoplasm: additional information on pathological tests].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Cetuximab; Colonic Neoplasms; ErbB Receptors; Gefitinib; Genes, ras; Genetic Testing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Mutation; Pharmacogenetics; Quality Control; Quinazolines | 2010 |
[Molecular targets in colon cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib | 2006 |
[Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer].
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Enzyme Inhibitors; Fluorouracil; Hospitalization; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quality of Life; Quinazolines; Rectal Neoplasms; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors | 1998 |
Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Quinazolines; Thiophenes; Tumor Cells, Cultured | 1999 |
A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Folic Acid Antagonists; Gene Expression; Humans; Ovarian Neoplasms; Peptide Synthases; Quinazolines; RNA, Messenger; RNA, Neoplasm; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 2002 |
6 trial(s) available for quinazolines and Colonic Neoplasms
| Article | Year |
|---|---|
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome; Young Adult | 2008 |
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Female; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2009 |
A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Quinazolines; Rectal Neoplasms | 2004 |
[Phase I study of raltitrexed (ZD-1694)].
Topics: Adult; Aged; Alanine Transaminase; Anorexia; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Colonic Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Quinazolines; Thiophenes; Thymidylate Synthase | 1998 |
[A late phase II study of raltitrexed (ZD 1694) in chemotherapy-naive patients with advanced colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Leukopenia; Male; Middle Aged; Quinazolines; Rectal Neoplasms; Thiophenes; Thymidylate Synthase | 2000 |
Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Rectal Neoplasms; Thiophenes; Treatment Outcome | 2000 |
174 other study(ies) available for quinazolines and Colonic Neoplasms
| Article | Year |
|---|---|
First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Humans; Quinazolines; Rectal Neoplasms; Retrospective Studies; Thiophenes | 2022 |
Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer.
Topics: Benzofurans; China; Colonic Neoplasms; Colorectal Neoplasms; Humans; Quinazolines; Retrospective Studies; Vascular Endothelial Growth Factor A | 2022 |
Efficacy and Safety Comparison of Regorafenib and Fruquintinib in Metastatic Colorectal Cancer-An Observational Cohort Study in the Real World.
Topics: Benzofurans; Colonic Neoplasms; Colorectal Neoplasms; Humans; Phenylurea Compounds; Prospective Studies; Pyridines; Quinazolines; Rectal Neoplasms; Retrospective Studies | 2022 |
A Novel Conjugate of Bis[((4-bromophenyl)amino)quinazoline], a EGFR-TK Ligand, with a Fluorescent Ru(II)-Bipyridine Complex Exhibits Specific Subcellular Localization in Mitochondria.
Topics: Cell Proliferation; Colonic Neoplasms; ErbB Receptors; Extranodal Extension; Fluorescent Dyes; Glioblastoma; Humans; Mitochondria; Protein Kinase Inhibitors; Quinazolines; Ruthenium; Subcellular Fractions | 2019 |
Scaffold Hopping of Natural Product Evodiamine: Discovery of a Novel Antitumor Scaffold with Excellent Potency against Colon Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Drug Design; G2 Phase; HCT116 Cells; Humans; Mice; Quinazolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tubulin Modulators; Xenograft Model Antitumor Assays | 2020 |
BMP9 mediates the anticancer activity of evodiamine through HIF‑1α/p53 in human colon cancer cells.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Growth Differentiation Factor 2; HCT116 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Phosphorylation; Quinazolines; Tumor Suppressor Protein p53; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Tolerability of pemetrexed and oxaliplatin in the treatment of stage III colon cancer during raltitrexed shortage.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Canada; Colonic Neoplasms; Female; Humans; Kidney Diseases; Middle Aged; Oxaliplatin; Pemetrexed; Quinazolines; Thiophenes; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Targeting tumor cells based on Phosphodiesterase 3A expression.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carrier Proteins; Cell Line, Tumor; Colonic Neoplasms; Cyclic Nucleotide Phosphodiesterases, Type 3; Female; Gastrointestinal Stromal Tumors; Gene Expression; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Organ Specificity; Organoplatinum Compounds; Oxaliplatin; Phosphodiesterase Inhibitors; Pyridazines; Quinazolines; RNA, Messenger; Skin Neoplasms | 2017 |
Novel β-phenylacrylic acid derivatives exert anti-cancer activity by inducing Src-mediated apoptosis in wild-type KRAS colon cancer.
Topics: Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; ErbB Receptors; Gefitinib; Genes, src; HCT116 Cells; HT29 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines; Signal Transduction; src-Family Kinases | 2018 |
FOXO1 degradation via G9a-mediated methylation promotes cell proliferation in colon cancer.
Topics: Apoptosis; Azepines; Cell Proliferation; Colonic Neoplasms; CRISPR-Cas Systems; DNA Methylation; Female; Flow Cytometry; Forkhead Box Protein O1; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; HCT116 Cells; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Male; Quinazolines; S-Phase Kinase-Associated Proteins; Tissue Array Analysis; Ubiquitination | 2019 |
Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colonic Neoplasms; Crizotinib; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Quinazolines; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Neovascularization, Pathologic; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Multitargeted low-dose GLAD combination chemoprevention: a novel and promising approach to combat colon carcinogenesis.
Topics: Adenomatous Polyps; Animals; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Carcinogenesis; Cell Proliferation; Chemoprevention; Colon; Colonic Neoplasms; Cytokines; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Eflornithine; Female; Gefitinib; Heptanoic Acids; Intestine, Small; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Pyrroles; Quinazolines | 2013 |
Serum regulation of Id1 expression by a BMP pathway and BMP responsive element.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Blotting, Western; Bone Morphogenetic Protein Receptors; Bone Morphogenetic Proteins; Cells, Cultured; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Differentiation Protein 1; Luciferases; Mice; NIH 3T3 Cells; Promoter Regions, Genetic; Quinazolines; Real-Time Polymerase Chain Reaction; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Serum; Signal Transduction; Smad Proteins; src-Family Kinases | 2013 |
Label-free imaging of drug distribution and metabolism in colon cancer cells by Raman microscopy.
Topics: Cell Line, Tumor; Colonic Neoplasms; Erlotinib Hydrochloride; Humans; Microscopy, Confocal; Quinazolines; Spectrum Analysis, Raman | 2014 |
Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Heterografts; Humans; Mice, Inbred BALB C; Quinazolines; Receptor-Like Protein Tyrosine Phosphatases, Class 2; STAT3 Transcription Factor; Tyrphostins | 2014 |
A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorine Radioisotopes; Fluorobenzenes; Humans; Imidazoles; Immunoblotting; Immunohistochemistry; Indoles; Mice, Inbred C57BL; Mice, Nude; Organophosphates; Peptides; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Quinolines; Radiopharmaceuticals; Sulfonamides; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Synergism; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Label-free single cell kinetics of the invasion of spheroidal colon cancer cells through 3D Matrigel.
Topics: Biosensing Techniques; Cell Culture Techniques; Cell Movement; Collagen; Colonic Neoplasms; Drug Combinations; Epidermal Growth Factor; HT29 Cells; Humans; Kinetics; Laminin; Microscopy; Piperidines; Protein Kinase Inhibitors; Proteoglycans; Quinazolines; Spheroids, Cellular | 2014 |
Variable NF-κB pathway responses in colon cancer cells treated with chemotherapeutic drugs.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Erlotinib Hydrochloride; Fluorouracil; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Phleomycins; Quinazolines; Signal Transduction | 2014 |
The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling.
Topics: Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Epidermal Growth Factor; ErbB Receptors; Gefitinib; HCT116 Cells; HEK293 Cells; HT29 Cells; Humans; MAP Kinase Signaling System; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Receptor-Like Protein Tyrosine Phosphatases, Class 3; RNA, Messenger; Signal Transduction; src-Family Kinases | 2014 |
EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; ErbB Receptors; Gefitinib; Gene Expression; Humans; Phosphorylation; Polycomb Repressive Complex 2; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering | 2014 |
Quinazoline based small molecule exerts potent tumour suppressive properties by inhibiting PI3K/Akt/FoxO3a signalling in experimental colon cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ehrlich Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Class Ia Phosphatidylinositol 3-Kinase; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Design; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; G1 Phase Cell Cycle Checkpoints; HCT116 Cells; Humans; Male; Membrane Potential, Mitochondrial; Mice; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden | 2015 |
Bioprospection of cytotoxic compounds in fungal strains recovered from sediments of the Brazilian coast.
Topics: Antineoplastic Agents; Biological Products; Brazil; Colonic Neoplasms; Fungi; Geologic Sediments; Gliotoxin; HCT116 Cells; Humans; Indoles; Phylogeny; Quinazolines | 2015 |
[Targeted therapy for solid tumors in the elderly].
Topics: Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Cetuximab; Colonic Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Trastuzumab | 2015 |
BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis.
Topics: Animals; Antigens, CD; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Glucose; Homeostasis; Humans; Mice; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Receptor, IGF Type 1; Receptor, Insulin; Receptors, Somatomedin; Xenograft Model Antitumor Assays | 2015 |
Antiproliferation effect of evodiamine in human colon cancer cells is associated with IGF-1/HIF-1α downregulation.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin-Like Growth Factor I; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2015 |
Development of certain new 2-substituted-quinazolin-4-yl-aminobenzenesulfonamide as potential antitumor agents.
Topics: Antineoplastic Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colon; Colonic Neoplasms; HT29 Cells; Humans; Quinazolines; Sulfonamides | 2016 |
Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Humans; Quinazolines; RNA, Small Interfering; Transcriptome; Tyrphostins | 2016 |
Gefitinib enhances human colon cancer cells to TRAIL-induced apoptosis of via autophagy- and JNK-mediated death receptors upregulation.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Colonic Neoplasms; Gefitinib; HT29 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Quinazolines; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2016 |
A comparative assessment of preclinical chemotherapeutic response of tumors using quantitative non-Gaussian diffusion MRI.
Topics: Animals; Bayes Theorem; Colonic Neoplasms; Diffusion Magnetic Resonance Imaging; Dimethyl Sulfoxide; Disease Models, Animal; Female; Humans; Mice; Mice, Nude; Models, Statistical; Organophosphates; Protein Kinase Inhibitors; Quinazolines | 2017 |
Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Feedback, Physiological; Humans; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Up-Regulation | 2017 |
Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines | 2017 |
Effect of evodiamine and berberine on the interaction between DNMTs and target microRNAs during malignant transformation of the colon by TGF-β1.
Topics: Animals; Animals, Newborn; Berberine; Cell Transformation, Neoplastic; Colon; Colonic Neoplasms; DNA (Cytosine-5-)-Methyltransferases; Gene Expression Regulation, Neoplastic; Immunoenzyme Techniques; MicroRNAs; Promoter Regions, Genetic; Quinazolines; Rats; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta1 | 2017 |
Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cell Survival; Cetuximab; Cluster Analysis; Colonic Neoplasms; Epidermal Growth Factor; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Microscopy, Electron, Scanning; Microvilli; Oligonucleotide Array Sequence Analysis; Quinazolines | 2008 |
Dual targeting of EGFR and HER-2 in colon cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
DNA damage and homologous recombination signaling induced by thymidylate deprivation.
Topics: Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; Flow Cytometry; Folic Acid; Folic Acid Antagonists; HeLa Cells; Humans; Nucleotides; Phosphorylation; Quinazolines; Rad51 Recombinase; Recombination, Genetic; Replication Protein A; Thiophenes; Thymidine Monophosphate; Thymidylate Synthase | 2008 |
Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Signal Transduction; Tumor Cells, Cultured | 2008 |
Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Humans; Irinotecan; Liver Diseases; Liver Neoplasms; Male; Quinazolines; Thiophenes | 2008 |
Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).
Topics: Animals; Carcinoma, Squamous Cell; Cell Movement; Colonic Neoplasms; Endothelium, Vascular; Female; Humans; Mice; Mice, Inbred C3H; Mice, Nude; Neovascularization, Pathologic; Piperidines; Quinazolines; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Proliferation; Chromatography, Liquid; Colonic Neoplasms; Colony-Forming Units Assay; Drug Synergism; ErbB Receptors; Flow Cytometry; Humans; Irinotecan; Lapatinib; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells.
Topics: Animals; Apoptosis; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; bcl-2-Associated X Protein; Benzamides; Benzazepines; Blotting, Western; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Flow Cytometry; Humans; Mice; Mice, Knockout; Mitosis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-mdm2; Quinazolines; Spindle Apparatus; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2009 |
Autophagy can contribute to cell death when combining targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Death; Colonic Neoplasms; HCT116 Cells; Humans; Indoles; Lapatinib; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines | 2009 |
Clinical significance of the KRAS mutation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Precision Medicine; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2009 |
Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation; Gene Knockdown Techniques; Humans; Male; Methotrexate; MicroRNAs; Middle Aged; Nuclear Proteins; Osteosarcoma; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Tetrahydrofolate Dehydrogenase; Thiophenes; Thymidylate Synthase; Transfection; Ubiquitin-Protein Ligases | 2010 |
Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Survival; Cetuximab; Colonic Neoplasms; ErbB Receptors; Female; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Xenograft Model Antitumor Assays | 2010 |
Evodiamine induces caspase-dependent apoptosis and S phase arrest in human colon lovo cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Endodeoxyribonucleases; Female; Humans; Mice; Mice, Nude; Plant Extracts; Quinazolines; S Phase; Signal Transduction | 2010 |
Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.
Topics: Adenoma; Animals; Antineoplastic Agents; beta Catenin; Colitis; Colonic Neoplasms; Dextran Sulfate; Disease Models, Animal; ErbB Receptors; Genes, APC; Intestine, Small; Mice; Mice, Inbred C57BL; Piperidines; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Colonic Neoplasms; Contrast Media; Humans; Image Enhancement; Kinetics; Male; Neovascularization, Pathologic; Piperidines; Quinazolines; Rats; Rats, Nude; Time Factors; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2010 |
Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Dideoxynucleosides; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; HCT116 Cells; Humans; Immunoblotting; Ki-67 Antigen; Methotrexate; Mice; Mice, Nude; Organophosphates; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Thymidine; Thymidine Kinase; Xenograft Model Antitumor Assays | 2011 |
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase B; Aurora Kinases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Mice; Mice, Nude; Organophosphates; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Quinazolines; Xenograft Model Antitumor Assays | 2011 |
Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Ligands; Male; Neoplasms; Neurokinin-1 Receptor Antagonists; Piperidines; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Neurokinin-1; Signal Transduction; Substance P; Trastuzumab | 2012 |
Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Electrophoresis, Polyacrylamide Gel; HCT116 Cells; HT29 Cells; Humans; Immunohistochemistry; Lapatinib; Mice; Mice, Nude; Microscopy, Fluorescence; Quinazolines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2011 |
Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
Topics: Blotting, Western; Breast Neoplasms; Cell Proliferation; Colonic Neoplasms; Enzyme Inhibitors; Female; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Male; Models, Molecular; Prostatic Neoplasms; Protein Binding; Protein Conformation; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2011 |
Novel irreversible EGFR tyrosine kinase inhibitor 324674 sensitizes human colon carcinoma HT29 and SW480 cells to apoptosis by blocking the EGFR pathway.
Topics: Anilides; Apoptosis; Carcinoma; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; HT29 Cells; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Tyrphostins | 2011 |
[Adverse effects of new oncologic therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab | 2011 |
The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Colonic Neoplasms; Drug Delivery Systems; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; HCT116 Cells; HT29 Cells; Humans; Quinazolines; Radiation-Sensitizing Agents; Recombinant Fusion Proteins; Signal Transduction | 2012 |
Colorectal cancer.
Topics: Antineoplastic Agents; Colonic Neoplasms; ErbB Receptors; Gefitinib; Genetic Therapy; Humans; Interferon-alpha; Quinazolines | 2011 |
The effect of combining interferon-alpha and gefitinib in human colon cancer cell lines.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Quinazolines | 2011 |
Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction.
Topics: Blotting, Western; Chromatin Immunoprecipitation; Colonic Neoplasms; Cytotoxicity, Immunologic; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; GPI-Linked Proteins; Humans; Intracellular Signaling Peptides and Proteins; Killer Cells, Natural; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation | 2012 |
Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model.
Topics: Animals; Cell Line; Cell Proliferation; Colitis; Colon; Colonic Neoplasms; Disease Models, Animal; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Trinitrobenzenesulfonic Acid | 2011 |
Cytotoxic potential of novel 6,7-dimethoxyquinazolines.
Topics: Antineoplastic Agents; Cell Survival; Colonic Neoplasms; Female; HCT116 Cells; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Mass Spectrometry; Ovarian Neoplasms; Quinazolines; Spectrophotometry, Infrared; Structure-Activity Relationship | 2012 |
Dietary calcium supplementation enhances efficacy but also toxicity of EGFR inhibitor therapy for colon cancer.
Topics: Animals; Antineoplastic Agents; Azoxymethane; Calcium; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Dietary Supplements; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Humans; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Quinazolines; Random Allocation; Tumor Burden; Tyrphostins | 2012 |
Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Apoptosis; Cell Culture Techniques; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; HT29 Cells; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Mice; Mice, Nude; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Sialic Acids; Sialyltransferases; Transfection; Xenograft Model Antitumor Assays | 2012 |
EGFR and PKC are involved in the activation of ERK1/2 and p90 RSK and the subsequent proliferation of SNU-407 colon cancer cells by muscarinic acetylcholine receptors.
Topics: Calcium; Carbachol; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Maleimides; Protein Kinase C; Quinazolines; Quinolones; Receptors, Muscarinic; Ribosomal Protein S6 Kinases, 90-kDa; Tyrphostins | 2012 |
EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Epidermal Growth Factor; Gefitinib; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplastic Stem Cells; Quinazolines; Signal Transduction | 2012 |
The effect of monoclonal antibody cetuximab (C225) in combination with tyrosine kinase inhibitor gefitinib (ZD1839) on colon cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colonic Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Quinazolines | 2012 |
Novel dithiocarbamic acid esters derived from 6-aminomethyl-4-anilinoquinazolines and 6-aminomethyl-4-anilino-3-cyanoquinolines as potent EGFR inhibitors.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; ErbB Receptors; Esters; Female; HCT116 Cells; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Quinolines; Structure-Activity Relationship | 2013 |
Synergic antitumor effect of SKLB1002 and local hyperthermia in 4T1 and CT26.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Histocytochemistry; Hyperthermia, Induced; Immunohistochemistry; Mice, Inbred BALB C; Necrosis; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Thiadiazoles; Treatment Outcome | 2014 |
Anti-invasive and metastatic activities of evodiamine.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Lewis Lung; Cell Movement; Colonic Neoplasms; Evodia; Female; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Plant Extracts; Quinazolines | 2002 |
Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Breast Neoplasms; Cell Death; Cell Division; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Endothelial Growth Factors; ErbB Receptors; Female; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Oligonucleotides; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Severe liver dysfunction after raltitrexed administration in an HCV-positive colorectal cancer patient.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Chemical and Drug Induced Liver Injury; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Viremia | 2003 |
Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells.
Topics: Amphiregulin; Animals; Cells, Cultured; Colonic Neoplasms; Dogs; EGF Family of Proteins; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, src; Glycoproteins; Growth Substances; Humans; Intercellular Signaling Peptides and Proteins; Kidney; Mucins; Muscle Proteins; Mutation; Neoplasm Invasiveness; Neuropeptides; Peptides; Phosphatidylinositol 3-Kinases; Proteins; Quinazolines; Receptors, Thromboxane; Signal Transduction; Transforming Growth Factor alpha; Trefoil Factor-1; Trefoil Factor-2; Trefoil Factor-3; Tumor Suppressor Proteins | 2003 |
The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA Adducts; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gefitinib; HT29 Cells; Humans; Inhibitory Concentration 50; Organoplatinum Compounds; Oxaliplatin; Precipitin Tests; Quinazolines | 2003 |
Transactivation of the epidermal growth factor receptor mediates cholinergic agonist-induced proliferation of H508 human colon cancer cells.
Topics: Acetylcholine; Animals; Atropine; Cell Division; CHO Cells; Cholinergic Agonists; Colonic Neoplasms; Cricetinae; Drug Interactions; Egtazic Acid; ErbB Receptors; Flavonoids; Humans; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Muscarinic Antagonists; Phosphatidylinositol 3-Kinases; Phosphorylation; Quinazolines; Ribosomal Protein S6 Kinases, 90-kDa; Transcriptional Activation; Tyrphostins | 2003 |
Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Caspase 3; Caspase 7; Caspase 8; Caspases; Caspases, Initiator; Cell Line; Cell Line, Tumor; Colonic Neoplasms; Cysteine Endopeptidases; DNA, Complementary; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; fas Receptor; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Interferon-gamma; Kinetics; Microtubule-Associated Proteins; Mitochondria; Multienzyme Complexes; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Retroviridae; RNA, Small Interfering; Signal Transduction; Survivin; Time Factors; Transfection; Tumor Suppressor Protein p53; Up-Regulation | 2003 |
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Topics: Adenocarcinoma; Agar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Cell Membrane; Cetuximab; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Piperidines; Precipitin Tests; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors | 2004 |
Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation.
Topics: Cell Division; Cell Line, Tumor; Colonic Neoplasms; ErbB Receptors; Humans; Kinetics; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Tyrosine Phosphatases; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, PAR-2; Transcriptional Activation; Trypsin; Tyrphostins | 2004 |
Inhibition by evodiamine of hepatocyte growth factor-induced invasion and migration of tumor cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Lewis Lung; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Evodia; Hepatocyte Growth Factor; Melanoma, Experimental; Mice; Neoplasm Invasiveness; Plant Extracts; Quinazolines | 2004 |
The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Division; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Synergism; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Irinotecan; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2004 |
KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth.
Topics: Angiogenesis Inhibitors; Animals; Cell Proliferation; Colonic Neoplasms; Endothelial Cells; Enzyme Activation; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Phosphorylation; Prostatic Neoplasms; Quinazolines; Rats; Rats, Nude; Transplantation, Heterologous; Tyrosine; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Synergistic antitumor activity of capecitabine in combination with irinotecan.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Thiophenes | 2005 |
Importance of preclinical investigations of the integration of capecitabine into polychemotherapy regimens.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Thiophenes | 2005 |
Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Synergism; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lovastatin; Lung Neoplasms; Mevalonic Acid; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2005 |
Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines.
Topics: Antineoplastic Agents; Cell Proliferation; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; Interferon-alpha; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured; Up-Regulation | 2005 |
Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Growth Processes; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Humans; Phosphorylation; Quinazolines; Receptor, ErbB-2; Tyrphostins | 2005 |
Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.
Topics: Antimetabolites; Colonic Neoplasms; DNA Damage; Drug Interactions; Folic Acid; Folic Acid Antagonists; Homeostasis; Humans; Indoles; Isoindoles; Quinazolines; Thiophenes; Trifluridine; Tumor Cells, Cultured | 2006 |
Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines.
Topics: Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Gefitinib; Genes, erbB-1; Humans; Protein Kinase Inhibitors; Proteome; Quinazolines; Receptor, ErbB-3 | 2005 |
Interferon-alpha promotes the anti-proliferative effect of gefitinib (ZD 1839) on human colon cancer cell lines.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Interferon-alpha; Quinazolines; Time Factors; Up-Regulation | 2005 |
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity; Stomach Neoplasms | 2005 |
The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Cyclin E; DNA Topoisomerases, Type II; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2005 |
Lysophosphatidic acid-induced effects in human colon carcinoma DLD1 cells are partially dependent on transactivation of epidermal growth factor receptor.
Topics: Cell Line, Tumor; Chemotaxis; Colonic Neoplasms; Dipeptides; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Humans; Interleukin-8; Lysophospholipids; Phosphorylation; Phosphotyrosine; Protease Inhibitors; Quinazolines; Transcriptional Activation; Tyrphostins | 2006 |
Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Binding Sites; Cell Proliferation; Colonic Neoplasms; ErbB Receptors; Female; Humans; KB Cells; Mice; Mice, Nude; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Rats; Ribose; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
Topics: Animals; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; ErbB Receptors; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Tyrphostins; Xenograft Model Antitumor Assays | 2006 |
Assessing EGFR mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Paraffin Embedding; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Survival Analysis | 2006 |
The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line.
Topics: Amino Acid Substitution; Antineoplastic Agents; Arginine; Carrier Proteins; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Folate Receptors, GPI-Anchored; Folic Acid Antagonists; Glutamates; Glycine; Guanine; Humans; Leucovorin; Methotrexate; Mutation; Pemetrexed; Phosphoribosylglycinamide Formyltransferase; Purines; Pyrimidines; Quinazolines; Receptors, Cell Surface; Thiophenes; Thymidylate Synthase | 2006 |
Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors.
Topics: Adenocarcinoma; Biological Transport, Active; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Enzyme Inhibitors; Fibrosarcoma; Fluorouracil; HT29 Cells; Humans; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Thymidine; Thymidylate Synthase; Time Factors; Tritium | 2006 |
[Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Disease Susceptibility; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Proteins; Quinazolines; Staphylococcal Skin Infections; Superinfection | 2006 |
Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Diphosphonates; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Insulin; Insulin-Like Growth Factor II; Phosphorylation; Protein Isoforms; Quinazolines; Receptor, IGF Type 1; Receptor, Insulin; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2006 |
Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; ErbB Receptors; G2 Phase; Humans; Organoplatinum Compounds; Oxaliplatin; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2006 |
Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts.
Topics: Animals; Cisplatin; Colonic Neoplasms; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Semaphorin-3A; Signal Transduction; Triazoles; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2006 |
Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chromatography, High Pressure Liquid; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Piperidines; Quinazolines; Signal Transduction; Time Factors | 2006 |
Compensatory increases in Her-2/neu activation in response to EGFR tyrosine kinase inhibition in colon cancer cell lines.
Topics: Apoptosis; Cell Line, Tumor; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2006 |
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2006 |
Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis.
Topics: Adenoma; Animals; Azoxymethane; beta Catenin; Carcinogens; Cell Transformation, Neoplastic; Colonic Neoplasms; Cyclin D1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; ErbB Receptors; Gefitinib; Genes, ras; Male; Mice; Mice, Inbred A; Mutation; Quinazolines; Signal Transduction; Up-Regulation | 2007 |
[Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Synergism; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2006 |
Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
Topics: Animals; Calibration; Cell Proliferation; Colonic Neoplasms; Contrast Media; Disease Models, Animal; Heart Ventricles; Hemodynamics; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Male; Neoplasm Transplantation; Organometallic Compounds; Piperidines; Quinazolines; Rats; Rats, Nude | 2008 |
Therapy of colon carcinoma: an oncology perspective. Interview with Piotr M. Czaykowski by Paul C. Adams.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Carcinoma; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Quinazolines; Rectal Neoplasms; Thiophenes | 2007 |
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Drug Administration Schedule; ErbB Receptors; Female; Humans; Irinotecan; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2007 |
Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity.
Topics: Animals; Aurora Kinase B; Aurora Kinases; Cell Cycle; Colonic Neoplasms; Cytochrome P-450 CYP3A; Electrophysiology; Ether-A-Go-Go Potassium Channels; Histones; Humans; Male; Mice; Mice, Nude; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Quinazolines; Rats; Rats, Wistar; Structure-Activity Relationship; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Gene Dosage; Genes, ras; HCT116 Cells; Humans; MAP Kinase Signaling System; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Quinazolines; ras Proteins; Resting Phase, Cell Cycle; RNA, Messenger | 2008 |
Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model.
Topics: Animals; Azoxymethane; CCAAT-Enhancer-Binding Protein-beta; Colonic Neoplasms; Cyclin D; Cyclins; Disease Progression; ErbB Receptors; Gefitinib; Male; Precancerous Conditions; Quinazolines; Rats; Rats, Inbred F344; STAT3 Transcription Factor; Transcription Factor AP-1 | 2008 |
Mutations of epidermal growth factor receptor in colon cancer indicate susceptibility or resistance to gefitinib.
Topics: Antineoplastic Agents; Blotting, Western; Colonic Neoplasms; Disease Susceptibility; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Mutagenesis, Site-Directed; Mutation; Quinazolines; Tumor Cells, Cultured | 2008 |
Improved synthetic routes to 5,8-dideazapteroylglutamates amenable to the formation of poly-gamma-L-glutamyl derivatives.
Topics: Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Colonic Neoplasms; Drug Evaluation, Preclinical; Folic Acid; Humans; Indicators and Reagents; Pteroylpolyglutamic Acids; Quinazolines; Structure-Activity Relationship | 1983 |
Effects of 5,8-dideazaisopteroylglutamate and its possible tri-gamma-glutamyl metabolite (5,8-dideazaisoPteGlu3) on colon adenocarcinoma, and the folate dependent enzymes thymidylate synthase and dihydrofolate reductase.
Topics: Adenocarcinoma; Animals; Cell Line; Colonic Neoplasms; DNA Replication; Drug Resistance; Female; Humans; Kinetics; Leukemia; Methotrexate; Methyltransferases; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Peptide Synthases; Quinazolines; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase | 1983 |
Biochemical and antitumor effects of 5,8-dideazaisopteroylglutamate, a unique quinazoline inhibitor of thymidylate synthase.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Colonic Neoplasms; Female; Folic Acid Antagonists; Humans; Leukemia L1210; Methotrexate; Methyltransferases; Mice; Mice, Inbred C57BL; Quinazolines; Thymidylate Synthase | 1983 |
New therapeutic strategies for patients with gastrointestinal malignancies using biochemical modulation of fluorouracil.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colonic Neoplasms; Fatal Outcome; Fluorouracil; Folic Acid; Folic Acid Antagonists; Gastrointestinal Neoplasms; Gene Expression Regulation, Enzymologic; Humans; Interferon-alpha; Leucovorin; Liver Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; RNA, Messenger; RNA, Neoplasm; Thymidylate Synthase | 1995 |
Benzimidazo[1,2-c]quinazolines: a new class of antitumor compounds.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Division; Colonic Neoplasms; Crystallography, X-Ray; DNA; Humans; Intercalating Agents; Leukemia L1210; Molecular Conformation; Molecular Structure; Osteosarcoma; Quinazolines; Tumor Cells, Cultured | 1994 |
Destruction of WiDr multicellular tumor spheroids with the novel thymidylate synthase inhibitor 1843U89 at physiological thymidine concentrations.
Topics: Antineoplastic Agents; Carcinoma; Cell Division; Colonic Neoplasms; Humans; Indoles; Isoindoles; Methotrexate; Quinazolines; Thymidine; Thymidylate Synthase; Time Factors; Tumor Cells, Cultured | 1994 |
Benzo[f]quinazoline inhibitors of thymidylate synthase: methyleneamino-linked aroylglutamate derivatives.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Glutamates; Humans; Indoles; Isoindoles; Quinazolines; Structure-Activity Relationship; Thymidylate Synthase; Tumor Cells, Cultured | 1994 |
Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
Topics: Acyltransferases; Antineoplastic Agents; Cell Division; Cell Survival; Colonic Neoplasms; Folic Acid Antagonists; Humans; Hydroxymethyl and Formyl Transferases; Hypoxanthine; Hypoxanthines; Methotrexate; Phosphoribosylglycinamide Formyltransferase; Quinazolines; Tetrahydrofolates; Thiophenes; Thymidine; Thymidylate Synthase; Tumor Cells, Cultured | 1993 |
Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some 3-amino- and 3-methylbenzo[f]quinazolin-1(2H)-ones.
Topics: Adenocarcinoma; Cell Division; Colonic Neoplasms; Escherichia coli; Humans; Quinazolines; Structure-Activity Relationship; Thymidylate Synthase; Tumor Cells, Cultured | 1993 |
Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase.
Topics: Animals; Binding, Competitive; Breast Neoplasms; Cell Division; Colonic Neoplasms; Female; Humans; Indoles; Isoindoles; Leucovorin; Leukemia L1210; Leukemia, T-Cell; Methotrexate; Quinazolines; Structure-Activity Relationship; Subrenal Capsule Assay; Tetrahydrofolates; Thymidylate Synthase | 1993 |
Isolation and characterization of a human ileocecal carcinoma cell line (HCT-8) subclone resistant to fluorodeoxyuridine.
Topics: Antimetabolites, Antineoplastic; Cell Division; Colonic Neoplasms; Drug Resistance; Floxuridine; Fluorouracil; Humans; Methotrexate; Quinazolines; Tetrahydrofolates; Thiophenes; Thymidine Kinase; Thymidine Phosphorylase; Thymidylate Synthase; Tumor Cells, Cultured | 1993 |
Heterocondensed quinazolones: synthesis and protein-tyrosine kinase inhibitory activity of 3,4-dihydro-1H,6H-[1,4] oxazino-[3,4-b]quinazolin-6-one derivatives.
Topics: Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Magnetic Resonance Spectroscopy; Protein-Tyrosine Kinases; Quinazolines; Spectrophotometry, Ultraviolet; Structure-Activity Relationship; Tumor Cells, Cultured | 1996 |
Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines.
Topics: Blotting, Northern; Blotting, Western; Breast Neoplasms; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Folic Acid Antagonists; Humans; Quinazolines; Thiophenes; Time Factors; Tumor Cells, Cultured | 1996 |
DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Cycle; Cell Division; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Damage; DNA Replication; DNA, Neoplasm; G1 Phase; G2 Phase; Humans; Neoplasm Proteins; Quinazolines; S Phase; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1996 |
Synergy between the non-classical thymidylate synthase inhibitor AG337 (Thymitaq) and cisplatin in human colon and ovarian cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorouracil; Humans; Ovarian Neoplasms; Quinazolines; Tumor Cells, Cultured | 1996 |
Measurement of deoxyuridine triphosphate and thymidine triphosphate in the extracts of thymidylate synthase-inhibited cells using a modified DNA polymerase assay.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colonic Neoplasms; Deoxyuracil Nucleotides; DNA-Directed DNA Polymerase; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Kinetics; Pyrophosphatases; Quinazolines; Templates, Genetic; Thiophenes; Thymidylate Synthase; Thymine Nucleotides; Tumor Cells, Cultured | 1997 |
Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Fluorouracil; Humans; Nucleotides; Phosphoribosyl Pyrophosphate; Quinazolines; RNA, Neoplasm; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 1998 |
Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells.
Topics: Apoptosis; Colonic Neoplasms; Endopeptidases; Enzyme Inhibitors; ErbB Receptors; Humans; Ligands; Protease Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Irinotecan; Quinazolines; Thiophenes; Tumor Cells, Cultured | 1998 |
Colon cancer: new drug options improve on 5-FU.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1998 |
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Colonic Neoplasms; Enzyme Inhibitors; ErbB Receptors; Female; Genes, erbB-2; Humans; Male; Phosphorylation; Prostatic Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Recombinant Proteins; Transfection; Uterine Cervical Neoplasms; Vulvar Neoplasms | 1997 |
Drug-company decision to end cancer trial.
Topics: Advisory Committees; Antidotes; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colonic Neoplasms; Control Groups; Drug Industry; Europe; Fluorouracil; Humans; Leucovorin; Multicenter Studies as Topic; Quinazolines; Research Subjects; Thiophenes | 1999 |
Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: mechanisms and clinical implications.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Cell Division; Cell Survival; Colonic Neoplasms; DNA Damage; Drug Synergism; Enzyme Inhibitors; Humans; Quinazolines; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1999 |
Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer.
Topics: Antiviral Agents; Bromodeoxyuridine; Colonic Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; Fluorouracil; Ganciclovir; Genetic Therapy; Humans; Quinazolines; Simplexvirus; Thiophenes; Thymidine Kinase; Thymidylate Synthase; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Topics: Blotting, Western; Cell Cycle; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Humans; Immunohistochemistry; Indoles; Inhibitory Concentration 50; Isoindoles; Methotrexate; Quinazolines; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 1999 |
Safety of raltitrexed.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colonic Neoplasms; Humans; Quinazolines; Thiophenes | 1999 |
Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Colonic Neoplasms; Enzyme Inhibitors; Flow Cytometry; Fluorouracil; Genes, bcl-2; Genes, p53; Humans; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 2000 |
Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Colonic Neoplasms; DNA Damage; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; Humans; Indoles; Isoindoles; Pemetrexed; Quinazolines; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 1999 |
Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antineoplastic Agents; Apoptosis; beta Catenin; Cadherins; Colonic Neoplasms; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cytoskeletal Proteins; Enzyme Activation; Humans; Isoenzymes; Kinetics; Phosphodiesterase Inhibitors; Piperidines; Protein Kinases; Quinazolines; Sulindac; Trans-Activators; Tumor Cells, Cultured | 2000 |
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Temozolomide; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
Treatment of SW620 cells with Tomudex and oxaliplatin induces changes in 2-deoxy-D-glucose incorporation associated with modifications in glucose transport.
Topics: Antineoplastic Agents; Biological Transport; Cell Cycle; Colonic Neoplasms; Deoxyglucose; Enzyme Inhibitors; Flow Cytometry; Glucose; Humans; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Thymidylate Synthase; Time Factors; Tritium; Tumor Cells, Cultured | 2000 |
Raltitrexed-related pulmonary toxicity.
Topics: Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dyspnea; Female; Humans; Lung Diseases; Quinazolines; Radiography, Thoracic; Thiophenes | 2000 |
Effect of 2'-O-methyl antisense ORNs on expression of thymidylate synthase in human colon cancer RKO cells.
Topics: Colonic Neoplasms; Enzyme Inhibitors; Growth Inhibitors; Humans; Oligoribonucleotides, Antisense; Quinazolines; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 2001 |
Schedule-dependent synergism and antagonism between raltitrexed ("Tomudex") and methotrexate in human colon cancer cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Methotrexate; Quinazolines; Thiophenes; Tumor Cells, Cultured | 2001 |
Schedule-dependent interaction between raltitrexed and 5-fluorouracil in human colon cancer cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Humans; Quinazolines; Thiophenes; Tumor Cells, Cultured | 2000 |
Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Colonic Neoplasms; Diet; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Fluorouracil; Folic Acid; Folic Acid Antagonists; Glutamates; Guanine; Leucovorin; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Pemetrexed; Quinazolines; Thiophenes; Thymidine; Thymidine Kinase; Thymidylate Synthase | 2001 |
Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives.
Topics: Animals; Antineoplastic Agents; Cell Survival; Colonic Neoplasms; Doxorubicin; Drug Design; Drug Resistance, Neoplasm; Humans; Indicators and Reagents; Isoquinolines; Jurkat Cells; Leukemia P388; Lung Neoplasms; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Conformation; Molecular Structure; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2001 |
Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Fluorometry; Fluorouracil; Folic Acid Antagonists; Humans; Hydroxymethyl and Formyl Transferases; Phosphoribosylglycinamide Formyltransferase; Quinazolines; RNA, Neoplasm; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase; Tumor Cells, Cultured | 2000 |
Inhibitory effects of evodiamine on in vitro invasion and experimental lung metastasis of murine colon cancer cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Cell Division; Colonic Neoplasms; Female; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Transplantation; Plant Extracts; Quinazolines; Tumor Cells, Cultured | 2001 |
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Endothelial Growth Factors; ErbB Receptors; Female; Gefitinib; Humans; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Oligodeoxyribonucleotides, Antisense; Ovarian Neoplasms; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Thymidylate synthase inhibition induces p53 dependent and independent cell death.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspases; Colonic Neoplasms; DNA Damage; Enzyme Inhibitors; Fas Ligand Protein; Fluorouracil; Folic Acid Antagonists; Glutamates; Guanine; Humans; Membrane Glycoproteins; Pemetrexed; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
[Irinotecan and tomudex in the treatment of patients with advanced cancer of the large intestine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Quinazolines; Rectal Neoplasms; Thiophenes; Time Factors | 2001 |
Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy.
Topics: Animals; Cell Line; Colonic Neoplasms; Dinoprostone; Enzyme Inhibitors; ErbB Receptors; Gastric Mucosa; Genes, src; Humans; Hypertrophy; MAP Kinase Signaling System; Matrix Metalloproteinases; Mitogen-Activated Protein Kinase 1; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Transcriptional Activation; Tyrphostins | 2002 |
Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bromodeoxyuridine; Carrier Proteins; Cell Survival; Colonic Neoplasms; Dipyridamole; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Humans; Membrane Proteins; Nucleoside Transport Proteins; Quinazolines; Thioinosine; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 2002 |
Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa").
Topics: Antineoplastic Agents; Blotting, Western; Colonic Neoplasms; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Quinazolines; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Rapid development of resistance to antifolates in vitro: possible clinical implication.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Folic Acid Antagonists; Leukemia P388; Methotrexate; Mice; Quinazolines; Trimetrexate; Tumor Cells, Cultured | 1991 |
Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells.
Topics: Adenocarcinoma; Cell Survival; Colonic Neoplasms; Drug Synergism; Fluorouracil; Folic Acid; Interferon Type I; Leucovorin; Quinazolines; Recombinant Proteins; Thymidylate Synthase; Tumor Cells, Cultured | 1991 |
Carboxypeptidase G2 and trimetrexate cause growth delay of human colonic cancer cells in vitro.
Topics: Animals; Antineoplastic Agents; Carboxypeptidases; Cell Division; Colonic Neoplasms; Culture Media; Homocysteine; Humans; Methionine; Mice; Quinazolines; Rabbits; Trimetrexate; Tumor Cells, Cultured | 1990 |
Hypersensitivity reactions to trimetrexate.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Drug Hypersensitivity; Female; Folic Acid Antagonists; Humans; Infusions, Intravenous; Male; Middle Aged; Quinazolines; Trimetrexate | 1990 |
Uptake and metabolism of 5,8-dideazaisofolic acid in human colon carcinoma cells.
Topics: Adenocarcinoma; Biotransformation; Colonic Neoplasms; Folic Acid Antagonists; Humans; Methotrexate; Polyglutamic Acid; Quinazolines; Thymidylate Synthase; Tumor Cells, Cultured | 1988 |
Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colony-Forming Units Assay; Drug Interactions; Drug Synergism; Floxuridine; Fluorouracil; Folic Acid Antagonists; Humans; Methotrexate; Quinazolines; Trimetrexate; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1989 |
Activity of batracylin (NSC-320846) against solid tumors of mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Intraductal, Noninfiltrating; Cell Survival; Cells, Cultured; Colonic Neoplasms; Drug Administration Schedule; Drug Screening Assays, Antitumor; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Pancreatic Neoplasms; Quinazolines; Tumor Cells, Cultured | 1989 |
Endogenous thymidine and hypoxanthine are a source of error in evaluating methotrexate cytotoxicity by clonogenic assays using undialyzed fetal bovine serum.
Topics: Adenocarcinoma; Animals; Cattle; Cell Adhesion; Colonic Neoplasms; Colony-Forming Units Assay; Culture Media; Dose-Response Relationship, Drug; Humans; Hypoxanthines; Leucovorin; Methotrexate; Neoplastic Stem Cells; Quinazolines; Thymidine; Trimetrexate | 1986 |
Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells.
Topics: Adenocarcinoma; Colonic Neoplasms; DNA Replication; DNA, Neoplasm; Dose-Response Relationship, Drug; Humans; Leukemia; Methotrexate; Quinazolines; Trimetrexate; Tumor Cells, Cultured | 1987 |
Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Cell Line; Colonic Neoplasms; Drug Resistance; Floxuridine; Humans; Hypoxanthine; Hypoxanthines; Methotrexate; Nucleosides; Quinazolines; Thymidine | 1985 |
The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Folic Acid; Humans; Middle Aged; Quinazolines; Rectal Neoplasms; Thymidylate Synthase | 1988 |
Preclinical antitumor activity of batracylin (NSC 320846).
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation, Preclinical; Injections, Intraperitoneal; Leukemia P388; Leukemia, Experimental; Mice; Mice, Inbred Strains; Quinazolines; Tumor Cells, Cultured | 1988 |
A new antitumour agent, batracylin, selected by a preclinical solid tumour model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Screening Assays, Antitumor; Leukemia L1210; Leukemia P388; Melanoma, Experimental; Mice; Quinazolines | 1988 |
Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Female; Folic Acid; Humans; Male; Middle Aged; Quinazolines; Rectal Neoplasms | 1988 |
Synthesis of 5-chloro-5,8-dideaza analogues of folic acid and aminopterin targeted for colon adenocarcinoma.
Topics: Adenocarcinoma; Aminopterin; Cell Line; Chemical Phenomena; Chemistry; Colonic Neoplasms; Humans; Quinazolines; Structure-Activity Relationship | 1987 |
Mechanism of action of 5,8-dideazaisofolic acid and other quinazoline antifols in human colon carcinoma cells.
Topics: Cell Survival; Colonic Neoplasms; Drug Resistance; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Humans; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 1987 |